All News

lung.ILD.MD

ILD and ANCA: What to do?

d Ulrich Specks, MD

Several cohort studies conducted in Asia, Europe and the Americas have evaluated the clinical significance of antineutrophil cytoplasmic antibodies (ANCA) when detected in patients with interstitial lung disease (ILD) as well as the types of ILD encountered in patients with microscopic polyangiitis (MPA) and their effect on the prognosis of MPA.

Read Article
CART

CAR-T Product Shows Early Promise in Lupus

d

Five patients with systemic lupus erythematosus (SLE) in China have been treated with a potentially groundbreaking form of chimeric antigen receptor (CAR) T-cell therapy, researchers reported, with encouraging results after 3 months.

Read Article
IPF.CT_.jpg

High-Resolution CT in CTD-Interstitial Lung Disease

d Jack Cush, MD

A systematic review and meta-analysis examined the role of high-resolution computed tomography (HRCT) in diagnosing and characterizing interstitial lung disease (ILD) associated with connective tissue diseases (CTDs).

Read Article
GCA temporal artery

Methylprednisolone plus Methotrexate in Giant Cell Arteritis

d Jack Cush, MD

What is the optimal glucocorticoids (GC) regimen in giant cell arteritis (GCA)? Does methotrexate (MTX) work in GCA?  

Read Article
lung%2Cbright.jpg

Scleroderma-associated Interstitial Lung Disease

d Marcy B. Bolster, MD

While we know there are certain clinical features serving as predictors that patients with SSc may develop ILD, including diffuse skin disease and serologies such as anti-Scl-70 and Th/To antibodies, it is imperative that clinicians consider that any patient, particularly early in their disease course (5 years of disease since the first non-Raynaud phenomenon symptom) could develop ILD. 

Read Article
Scleroderma-associated Interstitial Lung Disease Since the first placebo-controlled randomized trial published nearly 20 years ago for the treatment of patients with SSc-ILD, evaluating cyclophosphamide vs. placebo, there have been several other randomized studies to guide the https://t.co/Dh7XpP6qhF
Dr. John Cush RheumNow ( View Tweet)
Panel of IPF assoc 8 biomarkers (eotaxin, Flt-3L, IL-8, MDC, MCP-1, MMP-2/7/9) tested in 2 RA-ILD cohorts (n 164). IPF multibiomarker scores higher in RA-ILF vs RA alone. Highest quartile had ~2 fold incr risk of prevalent & incident ILD https://t.co/vYg9iB4EtH https://t.co/5ZZx6gg7A4

Links:

Dr. John Cush RheumNow ( View Tweet)
Big Fat FDA Pink Slip (9.19.2025) Dr. Jack Cush reviews the news and journal reports from this week on RheumNow. Today we cover GLP-1 agonists, acupuncture, what JAKs won’t do & an FDA Pink Slip. https://t.co/Za39hxI8Qf https://t.co/yN4K9tOuTt

Links:

Dr. John Cush RheumNow ( View Tweet)
Should we be "scoring" comorbidity to predict outcomes? SLE metanalysis looked at Charlson Comorbidity index (CCI). 3 RCTs, 1175 SLE pts show higher CCI scores predicts increased all-cause mortality (OR 3.92(95% CI: 2.74–5.60) https://t.co/LXfsGo9iJq https://t.co/eK31lnFrJk

Links:

Dr. John Cush RheumNow ( View Tweet)
Post hoc analyses of (FUTURE 5) 541 active PsA pts Rx w/ secukinumab shows NO radiographic progression through 2 years of SEC was assoc with achieving LDA at Week 104. https://t.co/ZeI9z4Civa https://t.co/LCI6kZ1z0v

Links:

Dr. John Cush RheumNow ( View Tweet)
Did Hydroxychloroquine Reduce COVID-19 Mortality? A multicenter study investigated the association between hydroxychloroquine (HCQ) dosage and COVID-19 mortality among hospitalized patients from multiple medical centers in China. The analysis focused on dose effects of HCQ on https://t.co/BuHoMDwpuP
Dr. John Cush RheumNow ( View Tweet)
Comparative Frequency of Systemic autoimmune rheumatic diseases (SARDs) in Australia: - SLE 57.9 per 100K - Lupus nephritis 11.2 per 100K - SSc 25.6 per 100K - ANCA-associated vasculitis 10.8 per million PYs https://t.co/cx9LvswQ2E https://t.co/ltcXCw23bI

Links:

Dr. John Cush RheumNow ( View Tweet)
Report of 54 Sjögren dz pts w/ cutaneous vasculitis (CV); most had cryoglobulinemic vasculitis & hypergammaglob.vasculitis. Sjogrens w/ CV had higher risk of lymphoma. Type II cryoglob. vasculitis incr risk of mortality/lymphoma, renal dz, peripheral nerve involvement https://t.co/7UPFd2dSZU
Dr. John Cush RheumNow ( View Tweet)
Sucutaneous anifrolumab? Phase III TULIP-SC trial in SLE patients showed SC anifrolumab (Saphnelo) significantly reducted lupus disease activity compared to placebo. https://t.co/vvI2av2vAJ https://t.co/0V1wsmFk0N

Links:

Dr. John Cush RheumNow ( View Tweet)
Single-center retrospective study 49 pts w/ primary angiitis CNS (PACNS) stratified by vessel size. Vessel size dx by imaging & neuroradiologists. Small vessel involv(n  9) was significantly assoc w/ +Biopsies, CTX use, functional decline & more relapses. https://t.co/DF6DknoPxY https://t.co/puc6nvEAut

Links:

Dr. John Cush RheumNow ( View Tweet)
Systematic review of 139 RCTs(9644 pts) & 12 Rx options for knee OA (KOA) shows simple Rx is best. For pain and function, knee brace was best, followed by exercise, and US worst. For total WOMAC best was hydrotherapy, then exercise & LaserTx. (Short wave diathermy worst) https://t.co/sN9TxJGn6N
Dr. John Cush RheumNow ( View Tweet)
🎓 Learning just got smarter. Every week, RheumIQ challenges you with a quick quiz on current rheumatology updates. 💡 Educational 🎯 Evidence-based 🧠 Addictive (in a good way) Try it now and level up your clinical knowledge: https://t.co/JWTPUViFkI https://t.co/DsKunA4DkQ

Links:

Dr. John Cush RheumNow ( View Tweet)
Worsening Breathlessness in SSc ILD Dr. Aurelie Najm, Glasgow, presents a QD Clinic on worsening breathlessness in systemic sclerosis interstitial lung disease, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025. https://t.co/P3MoM7ZmIo
Dr. John Cush RheumNow ( View Tweet)
GLP-1 Drugs Reduce Rheumatoid Arthritis Symptoms Patients with rheumatoid arthritis (RA) who used GLP-1 receptor agonists had less disease activity and improved cardiovascular biomarkers, a small retrospective study indicated. https://t.co/x2soZxuZCO https://t.co/84lnQOzsvP

Links:

Dr. John Cush RheumNow ( View Tweet)
What you need to know about scleroderma-related lung fibrosis What do you need to know about scleroderma-related lung fibrosis as a practicing rheumatologist? https://t.co/Ezl5G5IZeI https://t.co/zTF4lIYCAJ

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×